Resources
7 Results (showing 1 - 7)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 3/2/2021 (updated 4/5/2024)
As state policymakers confront the substance use disorder (SUD) epidemic, they require a wide range of data – often found in disparate systems – to understand its impact and craft more effective treatment programs and interventions. This report explores best practices and sources for data gathering and describes how states can help communities access and use data to support local efforts.
Posted 11/4/2020 (updated 4/3/2024)
This brief seeks to further the limited research, policy, and practice on substance use coercion and to increase awareness about this issue among relevant stakeholders.
Posted 9/30/2020 (updated 3/29/2024)
This packet presents Implementation II grantees with tools and strategies to support implementation activities that expand the options for SUD/OUD services across the care spectrum, thereby helping rural residents in your community to prevent SUD/OUD, access treatment, and move toward recovery.
Posted 2/4/2020 (updated 3/28/2024)
A Systems Perspective of the Opioid Epidemic Webinar Presentation and Materials
Posted 6/15/2020 (updated 3/28/2024)
The Opioid Use Disorder, Pregnant Women and Neonatal Abstinence Syndrome (NAS): Addressing the Challenges (Part II) webinar took place on June 9, 2020.
Posted 2/28/2023 (updated 3/27/2024)
Researchers looked at records for 917 patients who engaged with a peer recovery coach via telehealth after discharge from emergency departments for opioid use. The investigation focused on one Indiana-based hospital system that included six hospitals located in cities and seven that had rural Critical Access Hospital designations.
Posted 3/22/2022 (updated 3/27/2024)
The purpose of this document is to provide detailed guidelines of the Nurse Care Manager Model of Office Based Addiction Treatment program for management of substance use disorders, with particular emphasis on treatment of opioid use disorder with buprenorphine (alone and in combination with naloxone) and naltrexone (oral and extended-release injectable formulations).